Zhejiang Medicine Hits Day High with Strong 3.31% Intraday Surge

Zhejiang Medicine Co., Ltd. has experienced a notable uptick in its stock performance, gaining 3.31% on March 27, 2026. The stock reached an intraday high of CNY 16.05, reflecting a strong day of trading for the large-cap pharmaceutical and biotechnology company. In terms of performance metrics, Zhejiang Medicine has shown resilience with a year-to-date increase of 14.72%, significantly outperforming the China Shanghai Composite, which has declined by 1.39% during the same period. Over the past week, the stock has risen by 4.61%, contrasting with a slight dip in the broader market. Financially, the company has reported positive results for the last four consecutive quarters, with operating cash flow reaching a peak of CNY 2,018.84 million. The firm maintains a solid cash position, with cash and equivalents totaling CNY 6,124.58 million. Despite a modest annual growth rate in net sales of 4.64% over the last five years, the company boasts a return on equity of 12.47%, indicating a favorable valuation. Overall, Zhejiang Medicine's recent performance highlights its position within the pharmaceuticals and biotechnology sector, showcasing a blend of stability and growth potential.